New partnership between GSK and the Bill & Melinda Gates Foundation to accelerate research into vaccines for global health needs
- Details
- Category: GlaxoSmithKline
GSK and the Bill & Melinda Gates Foundation (BMGF) have announced the launch of a new joint initiative that will endeavour to make vaccines more resistant to heat, thus reducing the need for refrigeration. GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability.
Pfizer reports third quarter 2013 results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2013. Reported revenues decreased $310 million, or 2%, which reflects an operational decline of $38 million, or less than 1%, and the unfavorable impact of foreign exchange of $272 million, or 2%. The operational decrease was primarily the result of the continued erosion for branded Lipitor in the U.S., developed Europe and certain other markets.
AstraZeneca advances MedImmune's benralizumab to Phase III in severe asthma
- Details
- Category: AstraZeneca
AstraZeneca today announced the start of the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company's global biologics research and development arm. The goal of CALIMA, the first study in the Windward programme, is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled, despite receiving high doses of inhaled corticosteroids in combination with a second controller such as a long-acting beta agonist.
Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim
- Details
- Category: Boehringer Ingelheim
The Global Lung Cancer Coalition (GLCC) announced today, at the 15th World Conference on Lung Cancer (WCLC) in Sydney, Australia, a campaign, supported by Boehringer Ingelheim (BI), to increase the knowledge and understanding of real world challenges facing individuals and families battling lung cancer. 'Lung Cancer: We're Listening' will gather much needed feedback from individuals touched by lung cancer - including patients, carers, family members, friends, healthcare professionals and work colleagues.
Amgen's third quarter 2013 revenues increased 10 percent
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) has announced results for the third quarter of 2013. Total revenues increased 10 percent to $4,748 million, with 11 percent product sales growth driven by strong performance across the portfolio, particularly from Neulasta® (pegfilgrastim), Enbrel® (etanercept), Prolia® (denosumab) and XGEVA® (denosumab).
Bristol-Myers Squibb reports third quarter 2013 financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has reported results for the third quarter of 2013 highlighted by the strong performance of key marketed products such as Yervoy, Orencia and Sprycel, the presentation of important clinical data for its immuno-oncology pipeline, and the presentation of key cardiovascular outcomes data for Onglyza®.
Novartis delivers strong sales performance in third quarter
- Details
- Category: Novartis
Group net sales increased 4% (+6% cc) to USD 14.3 billion in the third quarter, with all divisions contributing to growth in constant currencies. Currency had a negative impact of 2 percentage points, mainly from the weakened yen and weakening emerging market currencies. Excluding the impact of patent expiries, underlying net sales grew 10% in constant currencies.
More Pharma News ...
- Amgen acquires Filgrastim franchise rights from Roche In 100 markets
- GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab)
- Roche posts strong sales growth in the first nine months of 2013
- Abbott reports third-quarter 2013 results
- AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
- AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment
- Novartis launches fully interactive Facebook ‘Retina App’ on World Sight Day to raise awareness of retinal disease